Helicobacter Pylori Test and Treat: How the Strategy and 2024 Guideline Work

Helicobacter pylori test and treat is a three-step logic: confirm an active infection with a noninvasive test, prescribe a course of antibiotics chosen to beat local resistance, then re-test to prove the organism is gone. In September 2024 the American College of Gastroenterology rewrote the middle and final steps. Its clinical guideline, published in the American Journal of Gastroenterology by William Chey, Colin Howden, Steven Moss and colleagues, names optimized bismuth quadruple therapy as the preferred first-line regimen for most adults, advises against empiric clarithromycin triple therapy, and makes a documented test of cure mandatory after every course. Each change answers the same problem: drugs that reliably cleared H. pylori two decades ago now fail often enough to matter.

Starting with the test

The "test" half of the strategy relies on assays that detect a living infection, not a past exposure. The urea breath test and the stool antigen test both do this well, with high sensitivity and specificity, and both can be repeated later to confirm cure. Serology behaves differently. Antibody tests stay positive for months or years after the bacterium is eradicated, so a positive result cannot separate current infection from an old one, and false positives climb in populations where infection is uncommon. For that reason the guideline steers clinicians toward breath or stool testing and away from blood antibody testing when the question is whether a patient is infected right now.

The strategy is most familiar in the workup of uninvestigated dyspepsia. The 2017 ACG and Canadian Association of Gastroenterology dyspepsia guideline recommends that patients younger than 60 without alarm features be tested noninvasively for H. pylori and treated if positive, reserving endoscopy for older patients or those with warning signs. Testing without an intention to treat, or treating without confirming the result, defeats the purpose.

Why clarithromycin fell out of first-line use

For years the default was a proton pump inhibitor plus clarithromycin and amoxicillin for one to two weeks. That regimen depends on the bacterium staying susceptible to clarithromycin, and in much of North America it no longer does. The 2024 guideline notes that clarithromycin and levofloxacin resistance have risen sharply, and that eradication rates fall to roughly 30 percent when the strain is clarithromycin-resistant. Despite this, proton pump inhibitor plus clarithromycin triple therapy remained the most commonly prescribed treatment. The guideline now recommends against using it empirically unless susceptibility testing has confirmed the strain is sensitive, which is rarely done in routine practice. Amoxicillin resistance, by contrast, remains low, in the low single digits, part of why amoxicillin-containing alternatives held up better in trials.

What "optimized" bismuth quadruple therapy means

The preferred regimen for treatment-naive adults, and for those who already failed clarithromycin triple therapy, is a 14-day course of optimized bismuth quadruple therapy. That combination pairs acid suppression with bismuth, tetracycline, and metronidazole. The word "optimized" carries weight. It means each component is given at full strength for the full 14 days, because underdosing the antibiotics or cutting the course short is where older bismuth regimens lost ground. The guideline lists this as its preferred empiric regimen for adults when antibiotic susceptibility is unknown.

Bismuth quadruple therapy is demanding, with four different medicines taken several times a day, so the guideline also recognizes alternatives. Rifabutin-based triple therapy and potassium-competitive acid blocker regimens are among them; a potassium-competitive acid blocker such as vonoprazan is a newer class of drug that raises stomach pH more consistently than a traditional proton pump inhibitor. These are explanations of approved treatment categories, not endorsements of any product, and the right choice depends on allergy history, prior antibiotic exposure, and tolerability.

Test of cure is no longer optional

The most consequential procedural change may be the last step. The guideline states that eradication should be confirmed in every patient after treatment, using a stool antigen test, urea breath test, or gastric biopsy. Timing is what people get wrong. Testing too soon produces false negatives, so it should wait until at least four weeks after antibiotics are finished and at least two weeks after stopping any proton pump inhibitor or potassium-competitive acid blocker, since acid suppression can also blunt the assays. Patients who need symptom relief in that window can often use H2-receptor antagonists or antacids, which do not interfere in the same way. Serology, again, has no role here, because it will not turn negative even after a successful cure.

Who the strategy is for

The 2024 guideline also widens the net for who should be tested and treated. Beyond active peptic ulcer disease, it supports testing people at increased risk of gastric cancer, those with atrophic gastritis or gastric intestinal metaplasia, and household members of infected adults, using non-serologic tests. That expansion reflects the standing of H. pylori as a World Health Organization Class I carcinogen and its causal link to gastric mucosa-associated lymphoid tissue lymphoma. Eradicating the infection can lower gastric cancer risk, and it also allows an ulcer to heal.

The through-line across all of this is stewardship. Matching therapy to resistance, finishing a full optimized course, and verifying the result protect both the individual patient and the shrinking supply of antibiotics that still work against this organism. This article is educational and not a substitute for individual medical advice.